HBIO: Gunggunge utang jangka dawa Harvard Bioscience Inc.

Harvard Bioscience (HBIO) operations are constrained by US-China trade barriers and logistical disruptions in Asia. Stable revenue is driven by customer lock-in to specialized software and maintenance services. The share price retrospective demonstrates the 0.04 indicator. Current growth is supported by the upgrading of automated lines, enabling the company to more rapidly process the backlog of orders for precision equipment.

HBIO Harvard Bioscience, Inc.: Utang jangka dawa perusahaan ing interval 04.07.2022 - 28.10.2026

Rincian analitis perusahaan Harvard Bioscience

- rega lan prakiraan konsensus rega:

Kurs saham harvardbioscience.com|HBIO - Prakiraan konsensus analis

- data kapitalisasi pasar:

Kapitalisasi pasar Harvard Bioscience|HBIO - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi saben Saham Harvard Bioscience|HBIO - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku harvardbioscience.com|HBIO - Aset Agregat Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Harvard Bioscience|HBIO - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Harvard Bioscience Inc.|HBIO - Gunggung utang perusahaan|Utang-utang marang aset resik Harvard Bioscience|HBIO - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Harvard Bioscience

Analisis umum perusahaan:harvardbioscience.com (HBIO)

This metric reflects the total volume of liabilities with maturities exceeding twelve months, allowing for an assessment of long-term financial stability and leverage levels relative to industry peers. By analyzing the long-term debt statistics of Harvard Bioscience (HBIO), an investor can confirm the current priority of Harvard Bioscience (HBIO) to optimize margins and integrate assets during a temporary hiatus from new merger and acquisition deals.

Analisis pesaing